Newsroom | Contact
Our proprietary technology platform enables the development of effective and differentiated products in multiple indications, for which neurogenic inflammation is underlying.
We initiate collaborations:
> Launch of TEDRAⓇ, a cosmeceutical product developed between 2019-2021 to hydrate and soothe sensitive areas.
This product was tested and approved by the BURN FOUNDATION who whished to offer patients a quality topical product for soothing and hydrating painful scars.
> We are working on the development of a first line drug for diabetic peripheral neuropathic pain (DPNP) with a focus on preclinical development in 2022.
> Several other R&D programs are in the pipeline, in chronic inflammatory and neurodegenerative diseases.
Rue Bodegnée-Village 4B
4537 Verlaine, Belgium
Subscribe to our newsflash
View private policy
© 2021 OLYS PharmaⓇ | Legal notice | Design & production : Gabrielle PENNEROUX